The head of the Food and Drug Administration (FDA) says that while the Trump administration is taking the potential harms of marijuana use among youth “very seriously,” it’s also important to preserve access to cannabis for medical purposes—and that’s part of the thinking behind the push to federally reschedule it.
In an interview on Fox Business on Wednesday, FDA Commissioner Marty Makary was asked about a recent New York Times editorial published that called for safeguards around marijuana, citing contested data on the relationship between cannabis use and health issues such as psychosis.
“First of all, we’ve seen a dramatic increase in teens vaping with THC…in the four years prior to us coming into office. So we’re taking this very seriously, and we’re trying to understand this field of science with better research,” he said. “The marijuana today is not the marijuana of hippies. It’s 10 to 20 times stronger, and new research is showing that its effect on the developing adolescent mind is different than in an adult.”
“It can result in psychosis diagnoses later in life. So we are taking this very seriously, and it is a controlled substance in the Trump administration, and so that’s the state
Read full article on Marijuana Moment
